124 results about "Pathogenic genes" patented technology

The invention relates to the technical field of biology, in particular to a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention discloses a verticillium dahliae virulence gene VdPHO23like. The verticillium dahliae virulence gene VdPHO23like comprises a polynucleotide sequence for coding an amino acid sequence of SEQ ID NO: 3. According to the invention, expression of the gene is inhibited in a targeted manner through an RNA interference mediated gene silencing technology so as to weaken virulence of pathogenic bacteria, and an efficient, specific and environment-friendly comprehensive prevention and control strategy is provided for verticillium wilt of crops such as cotton.

The invention provides a topology and biological feature fusion-based virulence gene prediction method, which comprises the following steps of: obtaining a to-be-detected gene; inputting the to-be-detected gene into a trained DAVGAE model, and predicting the correlation degree of the to-be-detected gene and the disease to obtain a disease gene correlation prediction conclusion; wherein the DAVGAE model comprises a data enhancement module, an encoder and an inner product decoder. The problems of data sparsity and heterogeneous data integration in gene-disease association prediction can be effectively solved at least through a DAVGAE model formed by a data enhancement module, an encoder and an inner product decoder.

The invention relates to the technical field of bioinformatics, in particular to a biological information analysis system based on a large model technology, which comprises a data analysis calibration module, a problem disassembly module, an analysis task arrangement module, a result mapping module and a feedback iteration module. According to the method, genome comparison and clinical phenotype timestamps are dynamically calibrated, time sequence dislocation deviation is eliminated, base complementary pairing is combined with protein network anomaly screening, low-abundance collaborative variation capture is enhanced, genotype-phenotype discrete distribution quantifies and unifies multi-modal data benchmark, and the problem of multi-source heterogeneous standardization deficiency is solved; the method comprises the following steps: classifying and integrating pathogenic gene semantic weights by structural variation, balancing a statistical threshold and a biological function, dynamically optimizing an analysis sequence, synchronously covering a key mutation region, improving function annotation of a non-coding region, integrating gene expression clustering and protein network topology in a three-dimensional distribution manner, breaking through two-dimensional space limitation, performing closed-loop feedback to correct a threshold iteration elimination rule, and finally obtaining a high-quality gene expression cluster. And the genetic heterogeneity false positive rate is reduced.

The invention provides a vaccine target screening system based on calculation model simulation. The vaccine target screening system comprises a multi-source heterogeneous database, wherein the multi-source heterogeneous database integrates and standardizes pathogenic genes, protein structures, literatures and experimental data; the feature calculation module calls a calculation biological model to carry out structural analysis, immunogenicity simulation and stability prediction; the intelligent screening and sorting module applies a multi-objective optimization algorithm to perform parallel evaluation and outputs optimal target spots; a structure iteration optimizer automatically iteratively corrects the optimized target spots to generate a high-potential variant library; and the process suitability simulation module couples the variants with the preparation formula and the process parameters to simulate production storage behaviors and feeds back an optimization target. According to the invention, efficient screening and optimization of vaccine targets can be realized, the accuracy and efficiency of target screening are improved, the research and development cost is reduced, and the research and development process of vaccines is accelerated.

The invention discloses a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention relates to the technical field of biology, and provides a method for preventing and treating cotton verticillium wilt based on RNAi (RNA interference) as well as related components and application thereof. Specifically, the invention discloses application of the verticillium wilt prevention and treatment by a method for inhibiting or silencing the expression of verticillium dahliae pathogenic gene VdHDAC (coding protein of the verticillium dahliae pathogenic gene VdHDAC is shown as SEQ ID NO: 3), the core of the verticillium wihliae pathogenic gene VdHDAC is to provide dsRNA molecules capable of targeting the gene, and the positive-sense strand of the dsRNA molecules is preferably selected from SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 11. Based on the molecule, the invention further provides a recombinant vector containing the coding sequence, a recombinant microorganism, a transgenic disease-resistant plant and an RNAi pesticide preparation. The scheme can be realized through host-induced gene silencing, microorganism-mediated gene silencing or preparation treatment and the like, the virulence of pathogenic bacteria can be effectively reduced, and a new technical approach is provided for green prevention and control of verticillium wilt.

The invention relates to a pathogenic gene identification method and system based on multi-agent debate and a medium. The method comprises the following steps: acquiring gene detection data and clinical phenotype data; the data agent processes the acquired data, and calls a gene variation pathogenicity analysis operator and a molecular genetic large model to obtain first pathogenic gene information; the knowledge agent calls a molecular genetic large model to obtain second pathogenic gene information based on the first pathogenic gene information; the knowledge and data agents sequentially speak and debate pathogenicity of candidate pathogenic genes in the first or second pathogenic gene information on the basis of sorting results in the pathogenic gene information output by the knowledge and data agents; after each round of debate is finished, the debate agent judges whether the sorting results of the data and the knowledge agent on the candidate pathogenic genes are consistent or not, if the sorting results are consistent or the number of debate rounds reaches a threshold value, debate is finished, the debate agent conducts reasoning and outputs a result, and if not, the next round of debate is started. Compared with the prior art, the method has the advantages of no dependence on large-scale training data, high interpretability and the like.

This invention discloses a pathogenic gene of barley stripe bacterium. Pg00232 Its application. Barley stripe disease is a fungal disease caused by *Barley Stripe Pathogen*, which seriously affects barley yield and quality. Traditional control methods have limited effectiveness and pose environmental risks; breeding disease-resistant varieties is the best strategy. This invention provides pathogenicity information for *Barley Stripe Pathogen*. Pg00232 Genes, and obtained through RNA interference technology Pg00232 The mutant strain further confirmed that Pg00232 The influence of genes on the growth, development, and pathogenicity of barley stripe causal agent. This discovery provides technical support for subsequent large-scale screening of pathogenic mutants of barley stripe causal agent, promotes the isolation, identification, and pathogenic mechanism research of pathogenic genes, and contributes to the breeding and selection of disease-resistant varieties.

The application belongs to the technical field of biology, and specifically discloses a truncated mutant of ANKRD11 and application thereof. The ANKRD11 gene mutant is any one of the following: a nucleic acid, wherein the nucleic acid has a target fragment, and the target fragment is compared with a wild-type ANKRD11 gene with a sequence of SEQ ID NO. 1, nucleotides from No. 1910 to No. 1913 are deleted; a polypeptide, wherein the polypeptide has a p.K637Tfs*15 mutation compared with a protein encoded by a wild-type ANKRD11 gene with a sequence of SEQ ID NO. 2. The application also relates to application of a reagent for detecting the aforementioned ANKRD11 gene mutant in screening of a KBG syndrome risk population. In the present disclosure, the pathogenic gene spectrum of the KBG syndrome is widened, the understanding of the disease is strengthened, experience is provided for clinical screening and diagnosis of the disease, and a basis is provided for prenatal diagnosis.

The invention provides a nanoparticle penetrating cornea as well as a preparation method and application thereof. The nanoparticle comprises a cationic liposome G2-C14, an inner core formed by aliphatic polyester and an amphiphilic polymer, and a shell modified by polysaccharide, the hydrophobic drug and the siRNA are loaded in the inner core. According to the nano-particles provided by the invention, through polysaccharide surface modification, ocular surface adhesion and trans-epithelium transport capability are enhanced, multi-barrier penetration of the eye is realized, the nano-particles are effectively delivered to a focus area of posterior segment of the eye, the delivered siRNA targets to silence the expression of age-related macular degeneration pathogenic genes, and the hydrophobic drug removes active oxygen and inhibits release of inflammatory factors, so that the anti-aging effect of the nano-particles is improved. The focus thickness is synergistically reduced.

The present invention provides a mutant gene, detection and application that causes 3-methylglutaconic aciduria type VII. The mutant gene that causes 3-methylglutaconic aciduria type VII includes a compound heterozygous mutation at the CLPB:NM_030813.6:exon8:c.1016T>G:p.L339R site and the exon1:c.130delG:p.E44Sfs*5 site. The mutant gene can effectively distinguish patients with 3-methylglutaconic aciduria type VII from the normal population. Therefore, the pathogenic gene mutation of the present invention can be used as a biomarker for diagnosing 3-methylglutaconic aciduria type VII. The present invention can be used for screening or diagnosing the genetic diagnosis of 3-methylglutaconic aciduria type VII by detecting whether the subject carries the above-mentioned mutation. The detection kit provided by the present invention can be used to quickly and effectively predict or diagnose 3-methylglutaconic aciduria type VII.

The present invention belongs to the field of data mining technology and relates to a method for discovering the influence of key elements based on native-derivative topic transfer learning, including obtaining information including native topics and derived topics and related user information from an API interface provided by a social platform; constructing the early propagation network topology and propagation timing of derived topics, including using a joint distribution adaptive method to perform cross-domain feature adaptation on the content space of native topics and derived topics, and considering the sparsity of early data of derived topics, using an adversarial transfer learning method to compensate for the network structure; constructing a message-path-user ternary association graph of derived topics and performing cyclic iterative scoring to rank the influence of key elements of derived topics; the present invention can timely and accurately mine key elements in the early stage of the outbreak of derived topics, and the present invention can also be widely used in the precise placement of product advertisements, the discovery of important pathogenic genes, the prediction of popular research results, and the prevention of computer virus propagation.

The invention belongs to the field of medical diagnosis, and particularly relates to adolescent idiopathic scoliosis disease-causing gene mutation and a diagnostic reagent based on the adolescent idiopathic scoliosis disease-causing gene mutation, and it is found for the first time that the adolescent idiopathic scoliosis disease can be caused by GPER1 gene mutation (chr7: 1, 091, 747Ggt, C, hg38) through an exon sequencing technology. Research results of the invention can be used for early screening of adolescent idiopathic scoliosis virulence gene mutation carriers to provide prenatal and postnatal rearing guidance on one hand, and can provide molecular diagnosis basis for adolescent idiopathic scoliosis patients on the other hand to provide a new direction for research and development of related scientific research and medical diagnosis products on the other hand, so that the research and development of the adolescent idiopathic scoliosis virulence gene mutation carriers can be promoted. Wide application prospects and market values are realized.

The barley stripe disease (Barley stripe disease) is an important disease in the worldwide range, which is caused by pyrenopora graminea, and the disease is one of the diseases which are commonly generated in barley producing areas in China and are seriously harmful to the barley producing areas. At present, breeding and utilization of disease-resistant varieties are the most economical, effective and safe means for controlling the disease. The invention provides screening and identification of the virulence gene Pg00778 of the barley stripe pathogen, a Pg00778 mutant strain is obtained through RNA interference and overexpression methods, and the influence of the Pg00778 gene on the growth, development and pathogenicity of the barley stripe pathogen is further proved. Technical support is provided for subsequent large-scale screening of barley streak pathogen pathogenesis related mutant strains, and separation, identification and pathogenesis research of barley streak pathogen pathogenesis related genes are promoted.

The invention discloses preparation and application of a double-component dsRNA (double-stranded ribonucleic acid) medicament for enhancing resistance mutation risk capability of RNA (ribonucleic acid) pesticide to botrytis cinerea, and a key pathogenic gene of botrytis cinerea is any one or two of a botrytis cinerea global regulatory factor Vel1 gene or a galacturonic acid reductase Gar2 gene. The dsRNA is any one or two of dsRNAs targeting a Vel1 gene or a Gar2 gene, and efficient prevention and control of gray mold are achieved through key pathogenic links such as spore germination inhibition, hypha colonization and infection structure formation. In addition, the effectiveness of the RNA pesticide aiming at botrytis cinerea after single target gene mutation is evaluated through cooperative use of the combination of the double-component RNA, the ds-Gar2 and the ds-Vel1, the good effect of the double-target synergistic effect in the aspect of reducing the off-target risk is proved, and the practice and popularization of a green prevention and control technology in prevention and control of gray mold are promoted.

The present invention provides a primer combination, a kit, a detection system, a detection method and an application for detecting pathogenic gene mutations of familial Alzheimer's disease and APOE genotypes by means of constant temperature multiplex rapid detection. The method of the present invention uses the amplification refractory mutation system technology combined with the nicking endonuclease nucleic acid detection reaction isothermal amplification system to perform multiplex amplification on 14 sites including 12 hot spot mutations and 2 risk sites of the Alzheimer's disease pathogenic gene, and at the same time combines capillary electrophoresis for product analysis to perform genotyping detection.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

The application belongs to the technical field of gene diagnosis, and specifically discloses a PHEX gene mutant and application thereof. The application mainly relates to the PHEX gene mutant and application thereof, and specifically relates to application of a PHEX c.112_113insA mutation in screening of a product of X-linked hypophosphatemic rickets resistant to vitamin D. The disclosure widens the pathogenic gene spectrum of X-linked hypophosphatemic rickets resistant to vitamin D, strengthens the understanding of the disease by clinical doctors, provides experience for screening and diagnosis of the disease in the clinic, and also provides a basis for prenatal diagnosis.

The present invention relates to the field of molecular biology, and more specifically to a composition, kit, and application thereof for detecting ATP7B gene polymorphisms. This method uses a PCR-based fluorescent probe melting curve method to determine common single-nucleotide polymorphisms (SNPs) in the ATP7B gene, a pathogenic gene for hepatolenticular degeneration, in genomic DNA from human peripheral venous whole blood samples. Compared to traditional PCR-based SNP detection methods, this method enables multiplexed detection within a single tube, significantly improving detection throughput. Compared to first- and second-generation sequencing methods and other methods, it offers advantages such as ease of operation, low cost, and shortened detection time.

The invention discloses a probe group for detecting copy number variation of pathogenic genes of limb development defect diseases as well as a design method, a kit and application of the probe group, and belongs to the technical field of biomedicine. The probe group comprises probes of which the nucleotide sequences are as shown in SEQ ID NO. 1 to SEQ ID NO. 516. The invention also discloses a design method of the probe group, a kit comprising the probe group, and a method for detecting copy number variation of the pathogenic gene of the limb development defect disease by using the probe group or the kit. The probe group and the kit provided by the invention can realize high-throughput, high-resolution, high-accuracy and low-cost copy number variation detection.

The invention relates to a gene vector for CSF1R (Classical Sequence Factor 1R) related white matter encephalopathy as well as a construction method and application of the gene vector. The gene vector is AAV.MG1.1-Trem2. The gene vector disclosed by the invention can be used for increasing the expression content of the Trem2 of the microglial cells and compensating the dysfunction of the pathogenic gene CSF1R, so that the microglial cells can exert normal functions.

The present application relates to the technical field of biology, and relates to an siRNA targeting glioblastoma multiforme and a use thereof. Provided is an siRNA targeting glioblastoma multiforme. An antisense strand of this siRNA can specifically bind to a target nucleic acid to initiate degradation of the target nucleic acid, wherein the target nucleic acid comprises a pathogenic gene in glioblastoma multiforme, and the pathogenic gene in glioblastoma multiforme comprises a gene encoding ribonucleotide reductase subunit M2 and / or a gene encoding heat shock protein 47. Studies have shown that both the gene encoding the ribonucleotide reductase subunit M2 and the gene encoding the heat shock protein 47 have a significant correlation with the survival of patients with glioblastoma multiforme. The two genes can be used as therapeutic targets for glioblastoma multiforme. The siRNA capable of effectively knocking down the expression of the two genes in the patients with glioblastoma multiforme has great application prospects in the preparation of drugs for preventing and / or treating glioblastoma multiforme.

The invention relates to the technical field of bacterial detection, in particular to a primer composition for simultaneously detecting pathogenic bacteria genes and drug-resistant genes, a detection method and a detection device. The core of the invention lies in synchronous detection of two main bacteria causing sepsis, namely burkholderia pseudomallei and klebsiella pneumoniae, and key drug-resistant genes by using a loop-mediated isothermal amplification (LAMP) technology. Specifically, the primer composition comprises nucleotide sequences as shown in SEQ ID No.1-17, and can be used for detecting a burkholderia pseudomallei recA pathogenic gene, a kfB pathogenic gene of klebsiella pneumoniae, a quinolone antibiotic drug-resistant gene qnrA and a carbapenem antibiotic drug-resistant gene OXA-48 in a targeted manner. The primer composition disclosed by the invention can be used for simultaneously detecting various pathogenic bacteria genes and drug-resistant genes causing sepsis, the detection process is convenient, rapid and accurate, the detection result can be obtained within 40 minutes, and the detection effect is better.

The invention discloses a system for screening Reiye's syndrome based on NOD2 gene new pathogenic mutation. The invention provides a computer device. The computer device comprises a memory, a processor and a computer program stored in the memory, the processor executes the computer program to implement the following steps: receiving NOD2 gene data (cDNA sequence) of a person to be tested; the method comprises the following steps: reacting the NOD2 gene with any one of the following mutations in SEQ ID No.2 stored in a computer: c.380Cgt; t, c, 2657Cgt; t, c.328Ggt; a, c.1295Cgt is selected from the group consisting of the T, c, 1981Ggt; c, and c, 2452Agt; c) performing comparison; and according to a comparison result, outputting information about whether the to-be-detected person is or is suspected to be a patient with the Reiderson's syndrome or about the risk of suffering from the Reiderson's syndrome. The novel pathogenic gene mutation form related to the NOD2 gene of the patient with the Reidersi syndrome is found, the novel pathogenic gene mutation form can serve as a target object to be used for developing a reagent and a computer device for diagnosing or screening the Reidersi syndrome, and the novel pathogenic gene mutation form has important significance on diagnosis and screening of the Reidersi syndrome.

This invention relates to a kit and method for detecting pathogenic genes of hereditary macular degeneration (AMD). The kit includes a hybridization mixture containing a probe set for detecting AMD pathogenic genes. The probe set includes capture probes capable of simultaneously and specifically capturing pathogenic genes ABCA4, BEST1, PRPH2, ELOVL4, PROM1, IMPG1, IMPG2, EFEMP1, RP1L1, and TIMP3, as well as the pathogenic regions of MCDR3 and MCDR1. The capture probes capturing the pathogenic regions of MCDR3 and MCDR1 include probes with sequences shown in SEQ ID NO. 1-174 and SEQ ID NO. 175-235, respectively. This invention proposes a targeted amplification strategy for the non-coding pathogenic region of NCMD, successfully detecting two novel point mutations and one genomic structural variation, achieving the detection of point mutations and structural variations in non-coding regions.

The invention relates to the technical field of bacterial detection, in particular to a primer group for simultaneously detecting sepsis-related pathogenic bacteria genes and drug-resistant genes and a matched method and device. The pathogenic bacteria genes are a Hafnia alvei rpoB pathogenic gene and an enterococcus faecium NusG pathogenic gene, and the drug-resistant genes are an oxazolidinone antibiotic drug-resistant gene optrA and a polymyxin antibiotic drug-resistant gene mcr-1. The primer composition comprises a nucleotide sequence as shown in SEQ ID No. 1 to SEQ ID No. 16. The primer composition provided by the invention can be used for simultaneously detecting two pathogenic bacteria pathogenic genes and two drug-resistant genes causing sepsis, and the primer group has high specificity and high sensitivity and can be used for accurately detecting the pathogenic genes in the same reaction system. The kit can realize simple, rapid and accurate detection, is suitable for on-site rapid detection, and can provide a new technical means for sepsis detection.

The invention discloses a composition for improving skin inflammation as well as application and a production method of the composition. The composition is prepared from the following components in parts by weight: 2 to 6 parts of curcumin monocarbonyl analogue cyclodextrin inclusion compound and 0.3 to 0.5 part of allantoin. The curcumin monocarbonyl analogue cyclodextrin inclusion compound is prepared from the following components in parts by weight: 0.5 to 1.5 parts of curcumin monocarbonyl analogue and 98.5 to 99.5 parts of beta-cyclodextrin, and the composition is applied as a skin care product. Aiming at skin inflammation caused by chronic symptoms, NF-kappa B nuclear translocation is blocked, multi-target anti-inflammation is achieved, and the effect is better directly aiming at core pathogenic genes. The allantoin increases the dissolution and absorption of the curcumin monocarbonyl analogue cyclodextrin inclusion compound, promotes the hydration of cuticle and reduces the irritation to the skin; the use effect is milder, and the composition is more suitable for non-invasive dermatitis.

The invention discloses an application of a pathogenic factor of sugarcane smut in regulation and control of pathogenicity of sugarcane smut. The amino acid sequence of the pathogenic protein SsCyp64 is as shown in SEQ ID NO: 2, and the coding amino acid sequence of the pathogenic gene SsCYP64 is as shown in SEQ ID NO: 1. According to the invention, SsCYP64 is knocked out from a sugarcane smut wild type through a PEG-mediated protoplast transformation method, so that a knockout mutant is obtained; and respectively back-supplementing the gene in the knockout mutant to obtain a back-supplemented strain. The SsCYP64 has the advantages that the SsCYP64 knockout mutant has the advantages that the capability of forming double mycelia by sexual coordination is weakened, the sensitivity to H2O2 and the SDS stress tolerance are increased, and the pathogenicity is reduced, so that the SsCYP64 plays an important role in regulating the sexual coordination, the oxidation resistance, the SDS tolerance and the pathogenicity of the sugarcane smut. The invention provides a target gene for developing effective bactericides.

The invention provides a gene mutant and application thereof, and belongs to the technical field of gene detection. Specifically, compared with a wild ATRN gene, the nucleotide sequence of the gene mutant provided by the invention has the following mutations: c.1504Ggt; t; wherein the nucleic acid is DNA (Deoxyribose Nucleic Acid). According to the application, the pathogenic gene ATRN having a causal relationship with schizophrenia is confirmed, and mutation influencing the gene function may cause myelin sheath injury so as to cause schizophrenia.

This invention belongs to the field of biotechnology, specifically disclosing novel mutations of ANKRD11 and their applications. The ANKRD11 gene mutation can be any of the following: a nucleic acid having a target fragment, wherein the target fragment has a G repeat at position 4708 compared to the wild-type ANKRD11 gene with sequence SEQ ID NO.1; or a polypeptide having the p.E1570Gfs*71 mutation compared to the wild-type protein encoded by the ANKRD11 gene with sequence SEQ ID NO.2. The invention also relates to the application of reagents for detecting the aforementioned ANKRD11 gene mutation in screening individuals at risk for KBG syndrome. This disclosure broadens the pathogenic gene spectrum of KBG syndrome, enhances the understanding of the disease, provides experience for clinical screening and diagnosis of the disease, and also provides a basis for prenatal diagnosis.

This application relates to a screening device and medium for candidate pathogenic genes and variants of hemophagocytic lymphohistiocytosis (HLH), belonging to the field of gene sequencing analysis technology. The device includes: an acquisition module for acquiring the gene sequencing variant file of the subject; a preliminary filtering module for initially filtering variant sites in the gene sequencing variant file; a variant annotation module for annotating the variant sites in the initially filtered gene sequencing variant file to generate a variant annotation file; a secondary filtering module for secondary filtering of variant sites in the variant annotation file; and a screening module for screening the variant sites in the secondary-filtered variant annotation file based on a local variant library to obtain candidate pathogenic genes and variants. The local variant library stores gene sequencing data of patients with similar HLH phenotypes and their non-phenotyped family members. This application can rapidly and accurately screen for harmful mutations related to HLH.